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Background and aims: Plasma aldosterone has been associated with all-cause and cardiovascular mortality in
high-risk cardiovascular populations, including patients with heart failure, myocardial infarction and high-
risk coronary artery disease (CAD) patients. In the present study, we evaluated the association of plasma al-
dosterone levels with vascular events in a large prospective cohort of stable CAD patients recruited in an out-
patient setting. Moreover, we investigated the relationship between aldosterone and atherosclerotic burden.
Methods and results: Baseline plasma aldosterone levels were measured in 2699 subjects with CAD (mean age
60±10 years, 82% male). During a median follow-up of 4.7 years, 308 (11%) patients died, of which 203 were
from a vascular cause. Vascular endpoints of myocardial infarction, ischemic stroke or vascular death occurred
in 355 (13%) patients. Multivariable Cox regression analysis was performed, adjusting for multiple confounders.
Aldosterone (median 96 pg/mL, interquartile range 70–138 pg/mL, normal range 58–362 pg/mL) was indepen-
dently associated with major vascular events (hazard ratio (HR) 1.56, 95% conﬁdence interval (CI) 1.13–2.15)
and vascular mortality (HR 1.95, 95% CI 1.27–3.00). By multivariable regression analysis, aldosterone was also
associated with the presence of atherosclerosis in additional vascular territories (cerebrovascular disease and/
or peripheral artery disease) (p=0.026).
Conclusions: In patients with stable coronary artery disease, plasma aldosterone is independently associated
with the risk of major vascular events and vascular mortality and with atherosclerotic burden.© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Renin-angiotensin-aldosterone system (RAAS) activation is an im-
portant factor in the pathophysiology of cardiovascular disease.
Aldosterone is a hormone with mineralocorticoid activity that is
synthesized by the adrenal glands. As a component of the RAAS,
aldosterone is classically known to play a regulatory role in body
ﬂuid and electrolyte homeostasis, thus contributing to the develop-
ment of hypertension. Recent ﬁndings from experimental and clinical, University Medical Center, EA
ecine Lille, France. Tel.: +33 6
D, PhD, Pieter A. Doevendans,
E. Grobbee, MD, PhD, L. Jaap
Moll, MD, PhD, Guy E. Rutten,
Ltd. All rights reserved.studies have indicated that aldosterone might be involved in cardio-
vascular disease through a mechanism distinct from its contribution
to hypertension [1–3]. Under controlled experimental conditions,
RAAS activation and administration of aldosterone resulted in myo-
cardial and vascular ﬁbrosis, inﬂammation, and endothelial dysfunc-
tion; such physiologic perturbations are known to complicate the
atherosclerotic process [4–8].
The experimental associations between aldosterone and end-
organ damage have been supported by clinical data showing beneﬁt
of aldosterone blockade in patients with heart failure or left ventricu-
lar dysfunction after acute myocardial infarction (MI) [9–11]. Like-
wise, in patients with hypertension, aldosterone blockade induced
beneﬁcial vascular wall changes, on top of blood pressure effects [12].
Several observational studies of patients with heart failure have
revealed a strong association of aldosterone levels with increased
mortality and with an increased risk of a combined endpoint compris-
ing cardiovascular mortality, development of severe heart failure or
Table 1
Deﬁnitions of major vascular events.
Myocardial
infarction
At least two of the following criteria:
– Chest pain for at least 20 min, not disappearing after
administration of nitrates
– ST segment-elevation >1 mm in two following leads or a new left
bundle branch block on electrocardiogram
– Creatine kinase (CK)-elevation of at least two times the normal
value of CK and a MB-fraction >5% of the total CK
Ischemic
stroke
– Deﬁnite ischemic stroke: relevant clinical features that have caused an
increase in impairment of at least one grade on the modiﬁed Rankin
scale, accompanied by a fresh ischemic infarction on brain-scan
– Deﬁnite stroke, probably non-haemorrhagic: relevant clinical features
that have caused an increase in impairment of at least one grade on
themodiﬁed Rankin scale, without new (haemorrhagic) infarction on
brain-scan and without signs of recovering bleeding
Vascular
death
– Death from myocardial infarction
– Sudden death: unexpected cardiac death within 1 h after onset of
symptoms, or within 24 h given convincing circumstantial evidence
– Death from ischemic stroke
– Death from intracerebral hemorrhage
– Death from decompensated heart failure
– Death from rupture of abdominal aortic aneurysm
– Vascular death from other cause
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senting with an acute MI were found to be associated with increased
cardiovascular risk during follow-up, even in the absence of heart
failure or marked left ventricular dysfunction [17–19]. Clinically rele-
vant associations between aldosterone levels and patient outcome
have recently been demonstrated in individuals with coronary artery
disease (CAD) admitted for coronary angiography and including a
large proportion (40%) with an acute coronary syndrome (ACS)
[20]. Likewise, we demonstrated aldosterone levels to be associated
with an increased risk of cardiovascular and all-cause mortality in a
group of 807 patients undergoing elective percutaneous coronary
intervention, of whom 26% with a very recent history (2–7 days) of
an ACS [21].
However, both studies did not speciﬁcally investigate the associa-
tion between aldosterone and clinical outcome in the non-ACS popula-
tion and the prognostic value of aldosterone in patients with stable
CAD remains unknown. Similarly, the potential link between aldoste-
rone and the process of atherosclerosis has yet to be reported in the
literature.
Therefore, the primary objective of this study was to investigate
the association between plasma aldosterone levels and future vascu-
lar events in patients with stable CAD recruited for the Secondary
Manifestations of ARTerial disease (SMART) outpatient cohort study
[22]. In addition, we aimed to deﬁne the relationships between
baseline aldosterone levels and fatal vascular events or atherosclero-
sis burden.
2. Methods
The authors of this manuscript have certiﬁed that they comply with the Principles
of Ethical Publishing in the International Journal of Cardiology.
2.1. Study population
This study was approved by the Ethics Committee of the University Medical Centre
Utrecht (UMCU), The Netherlands, and all patients provided written informed consent.
Patients were derived from the SMART study, an ongoing, prospective outpatient
cohort study at the UMCU [22]. SMART was originally designed to determine the prev-
alence of concomitant arterial diseases and risk factors for atherosclerosis in a patient
population characterized by a high cardiovascular risk proﬁle. Study patients were
newly referred to the UMCU with symptomatic arterial disease (coronary heart dis-
ease, cerebrovascular disease, abdominal aortic aneurysm or peripheral arterial dis-
ease) or with traditional cardiovascular risk factors (hypertension, hyperlipidemia, or
diabetes mellitus). Enrolees were non-invasively screened to ascertain manifestations
of atherosclerotic diseases and risk factors other than the qualifying diagnosis, as pre-
viously described; brieﬂy, at baseline patients underwent a standardized vascular
screening programme, including laboratory tests, ultrasonography and completion of
a health questionnaire (described below).
For the current study, we extracted the data of 2862 consecutive patients enrolled
between September 1996 and March 2008 and having established coronary artery dis-
ease. Plasma aldosterone levels were available for 2810 (98%) of the patients. Fifty-two
patients were excluded based on reported administration of aldosterone-blocking
agents, leaving a total of 2758 patients for analysis.
2.2. Deﬁnitions
CAD was deﬁned as a history of myocardial infarction or coronary revascularization
(coronary bypass surgery or coronary angioplasty).
Cerebrovascular disease was deﬁned as a history of transient ischemic attack, cerebral
infarction, amaurosis fugax, retinal infarction or carotid surgery.
Peripheral artery disease was deﬁned as a symptomatic and documented obstruc-
tion of distal arteries of the leg or surgery of the leg (percutaneous transluminal angio-
plasty, bypass or amputation).
Markers of atherosclerotic burden were identiﬁed as involvement of multiple vascular
territories (CAD plus at least one other manifestation of atherosclerotic vascular disease),
presence of carotid artery stenosis (>50%), ankle‐brachial index (ABI) and carotid
intima-media thickness.
Diabetesmellitus at baselinewas deﬁned as a documented history of diabetes or use of
glucose-lowering agents. In addition, subjects without a history of diabetes but with a
fasting plasma glucose level of ≥7.0 mmol/L at baseline and record of having received
treatment with glucose-lowering agents within 1 year after baseline attainment were con-
sidered as having diabetes at baseline.
Hypertension and hyperlipidemia were deﬁned as previously described [22].2.3. Data collection
At enrolment, patients were asked to complete a standardized questionnaire on
medical history, symptoms of and risk factors for cardiovascular disease, presence of
vascular disease in ﬁrst-degree relatives and current medication use. Furthermore, a
standardized diagnostic protocol was performed, including physical examination
(height, weight, waist circumference, systolic and diastolic blood pressure) and labora-
tory tests to determine fasting plasma lipid, glucose and insulin levels. For the purpose
of this study, aldosterone, B-type natriuretic peptide (BNP) and high-sensitivity
C-reactive protein (hsCRP) were measured (blinded to clinical data) in EDTA-plasma.
Aldosterone was measured by manual radioimmunoassay (Diagnostic Systems Labora-
tories, Beckman Coulter, Sinsheim, Germany). The inter-assay coefﬁcient of variation
ranged from 6 to 9% at 160 and 350–1100 pmol/L, respectively. hsCRP was measured
on a DxC 800 routine chemistry system and BNP was analysed on a Dxl 800 immuno-
chemistry system (both from Beckman Coulter, Brea, California, USA).
To obtain reference values, measurements were repeated in 70 healthy volunteers.
2.4. Follow-up
During follow-up, patients were asked to complete a biannual questionnaire on
hospitalizations and outpatient clinic visits.
The primary outcome of interest for this study was the occurrence of vascular
events deﬁned as non-fatal MI, non-fatal stroke or vascular death (Table 1). Secondary
outcome of interest was vascular mortality. When a possible event was reported, hos-
pital discharge letters and results of relevant laboratory and radiology examinations
were collected. Death was reported by relatives of the participant, the general practi-
tioner or the vascular specialist treating the patient. Based on the information from
the questionnaire and/or the family, all events were audited by three members of
the SMART study Endpoint Committee, comprising physicians from the Departments
of Cardiology, Neurology and Vascular Surgery. Follow-up duration (years) was de-
ﬁned as the period between study enrolment and ﬁrst cardiovascular event or death
from any cause, date of loss to follow-up or the preselected censoring date of 1
March 2009.
2.5. Data analysis
Since plasma aldosterone was not normally distributed, aldosterone levels were
categorized into quartiles, segregated by sex. Next, the corresponding male and female
quartiles were merged to generate quartiles with equal proportions of men vs. women
in each (sex-pooled analysis). This was done to ensure comparable percentages of both
sexes in all quartiles, since aldosterone levels tend to be higher in women as compared
to men. The lowest quartile served as the reference group.
Cox proportional hazard analysis was performed to estimate hazard ratios (HR)
and corresponding 95% conﬁdence intervals (CI) for the occurrence of major vascular
events and for the occurrence of vascular death associated with plasma aldosterone
levels. If a patient had multiple events, the ﬁrst recorded event was used in the analy-
ses. Patients were censored if they were lost to follow-up. HRs were calculated both
across aldosterone quartiles, with quartile 1 as reference, and per quartile increment.
Cox proportional hazard analysis was also performed with aldosterone levels log-
transformed. For presentation purposes, results are displayed for quartile-based analyses.
Four models were constructed, the ﬁrst model being a crude model, including only al-
dosterone. In the second model adjustments were made for age and gender. In the third
model additional adjustments were made for systolic blood pressure, diabetes mellitus,
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of beta-blockers, diuretics, angiotensin converting enzyme (ACE)-inhibitors and angioten-
sin II-receptor blockers (ARBs), all considered as potentially confounding factors in the re-
lationship between plasma aldosterone and vascular events. In the fourth model we
additionally explored the effects of low-density lipoprotein (LDL)-cholesterol, smoking
and hsCRP, in order to assess the effect of plasma aldosterone levels on cardiovascular
risk while taking into account other established cardiovascular risk factors that could not
be considered as obvious confounders in the relationship between aldosterone and vascu-
lar events.
To investigate whether the relation between plasma aldosterone and vascular
events was modiﬁed by the duration of CAD at baseline or by the presence of vascular
disease at other locations (brain, legs, abdominal aorta) we included these interaction
terms in the Cox models. If the p‐value of the interaction term was ≤0.05, then effect-
modiﬁcation was considered to be present.
The association of aldosterone levels with atherosclerotic burden was analyzed
with univariable and multivariable linear or logistic regression analysis, as appropriate.
For this purpose, markers of atherosclerotic burden (described above) were consid-
ered. Again, aldosterone levels were entered into the models as sex-pooled quartiles.
In multivariable regression analysis age, gender, systolic blood pressure, diabetes
mellitus, BMI, creatinine clearance, LDL-cholesterol, hsCRP and current smoking were
included in the models as possible confounders.3. Results
3.1. Baseline characteristics
The baseline characteristics of the study population according to
aldosterone quartiles are displayed in Table 2.
The mean age of the 2699 subjects was 60±10 years and 497 pa-
tients (18%) were female. A history of myocardial infarction wasTable 2
Baseline characteristics of the study population according to plasma aldosterone concentra
Total population (n=2699) Quartile 1
n=673
Aldosterone range (pg/mL) b=74
Aldosterone median (pg/mL) 53 (43–61)
Age (years) 60±10
Female, n (%) 123 (18%)
Current smoking, n (%) 169 (25)
Body mass index (kg/m2) 27±4
Diabetes mellitus, n (%) 115 (17)
Family history of CAD, n (%) 158 (24)
History of myocardial infarction, n (%) 336 (50)
Time since ﬁrst manifestation of CAD (years) 1.0 (0.5–5.0)
First manifestation of CAD ≥1 year, n (%) 339 (51)
Systolic blood pressure (mmHg) 138±20
Diastolic blood pressure (mmHg) 80±11
Total cholesterol (mmol/L) 4.5 (3.8–5.2)
Triglycerides (mmol/L) 1.3 (1.0–1.9)
HDL-cholesterol (mmol/L) 1.1 (1.0–1.4)
LDL-cholesterol (mmol/L) 2.6 (2.0–3.3)
BNP (pmol/L) 13 (7.0–24)
hsCRP (mg/L) 1.7 (0.8–3.4)
Creatinine clearance (Cockroft mL/min) 79 (67–91)
ABI at rest 1.18 (1.09–1.25)
Medication use
Use of beta-blockers, n (%) 527 (78)
Use of antiplatelet medication, n (%) 558 (83)
Use of lipid lowering medication, n (%) 507 (75)
Use of ACE-inhibitors, n (%) 218 (32)
Use of ARBs, n (%) 64 (9.5)
Use of diuretics, n (%) 84 (13)
Territories affected by atherosclerosis
Coronary artery disease, n (%) 673 (100)
Cerebrovascular disease, n (%) 51 (8)
Peripheral artery disease, n (%) 59 (9)
No. of vascular territories affected
1 571 (85)
2 94 (14)
3 8 (1.2)
HDL: high-density lipoprotein cholesterol, LDL: low-density lipoprotein cholesterol, BNP: B-
index, ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker.
Data are mean±standard deviation (SD) or median (interquartile range) unless otherwise
Categories of vascular territories affected are not mutually exclusive.present in 53% (n=1426) of the patients. Diabetes mellitus was pre-
sent in 460 (17%) patients. The median plasma aldosterone level was
96 pg/mL with an interquartile range of 70–138 pg/mL. Median aldo-
sterone levels were higher in females (102, IQR 74–146 pg/mL) than
in males (94, IQR 68–137 pg/mL).
The aldosterone values measured are within the 95% reference
range as obtained by repeating the same measurements in 70 local
healthy control subjects (aged 40–65 years): 58–362 pg/mL.
3.2. Follow-up
The median follow-up period was 4.7 years (interquartile range
2.7–7.5), for a total follow-up of 13,396 person years. Sixty-eight of
the 2699 participants (2.5%) were lost to follow-up before the censor-
ing date, due to migration or withdrawal from the study. Median
follow-up duration in these 68 participants was 3.3 years (1.7–5.6).
3.3. Aldosterone levels, vascular events and vascular death
During follow-up 308 (11%) patients died, 203 (7.5%) from a vascu-
lar cause. Additional vascular events were recorded in 148 patients
(5.5%) having a myocardial infarction and 69 patients (2.6%) who suf-
fered from an ischemic stroke. The vascular endpoint of MI, ischemic
stroke or vascular death occurred in 355 (13%) patients. The cumulative
ﬁve-year risk for the vascular events was 9.0% (95%CI 7.6–10.3%) and
4.7% (3.7–5.6%) for vascular death.tion quartiles.
Quartile 2 Quartile 3 Quartile 4
n=677 n=679 n=670
68–102 94–146 >=137
83 (76–89) 114 (104–126) 178 (154–223)
60±10 60±10 60±10
125 (19%) 135 (18%) 124 (19%)
170 (25) 186 (27) 188 (28)
27±4 27±4 27±4
110 (16) 106 (16) 129 (19)
141 (21) 151 (22) 109 (16)
360 (53) 357 (53) 381 (57)
1.0 (0.5–6.0) 1.0 (0.5–6.0) 1.0 (0.5–8.0)
378 (57) 380 (57) 396 (61)
139±21 140±21 142±22
81±11 81±11 82±11
4.6 (4.0–5.4) 4.7 (4.0–5.4) 5.0 (4.2–5.8)
1.5 (1.1–2.1) 1.5 (1.1–2.0) 1.6 (1.1–2.4)
1.2 (1.0–1.4) 1.1 (0.9–1.4) 1.2 (0.9–1.4)
2.7 (2.1–3.3) 2.7 (2.1–3.3) 2.9 (2.2–3.7)
11 (5.0–23) 11 (5.0–21) 10 (5.0–21)
2.0 (0.9–3.8) 2.2 (1.1–4.4) 2.3 (1.1–4.5)
77 (65–90) 75 (63–90) 74 (59–88)
1.18 (1.09–1.25) 1.17 (1.08–1.25) 1.15 (1.02–1.24)
510 (75) 475 (70) 439 (66)
574 (84) 569 (84) 531 (79)
516 (76) 522 (77) 452 (68)
206 (30) 197 (29) 173 (26)
50 (7.4) 56 (8.2) 47 (7.0)
90 (13) 117 (17) 178 (27)
677 (100) 679 (100) 670 (100)
52 (8) 67 (10) 83 (12)
55 (8) 58 (9) 99 (15)
578 (85) 562 (83) 508 (76)
91 (13) 109 (16) 142 (21)
8 (1.2) 8 (1.2) 20 (3.0)
type natriuretic peptide, hsCRP: high-sensitivity C-reactive protein, ABI: ankle-brachial
stated.
Table 3
Hazard ratios of plasma aldosterone quartiles on the occurrence of vascular death and the composite endpoint of myocar-
dial infarction, stroke or vascular death.
Quartile 1 Quartile 2 Quartile 3 Quartile 4
n=673 n=677 n=679 n=670
Aldosterone range (pg/mL) <=74 68-102 94-146 >=137 
MAJOR VASCULAR EVENTS
VASCULAR MORTALITY
No. of events 64 80 81 126
Model I Reference 1.12 (0.81-1.56) 1.14 (0.82-1.58) 1.72 (1.27-2.33)
Model II Reference 1.12 (0.81-1.56) 1.12 (0.80-1.56) 1.70 (1.26-2.30)
Model III Reference 1.13 (0.81-1.59) 1.11 (0.79-1.56) 1.56 (1.13-2.15)
Model IV Reference 1.16 (0.82-1.63) 1.13 (0.80-1.60) 1.51 (1.08-2.11) 
No. of events 33 42 42 86
Model I Reference 1.11 (0.70-1.75) 1.12 (0.71-1.76) 2.18 (1.45-3.26)
Model II Reference 1.15 (0.73-1.81) 1.09 (0.69-1.72) 2.09 (1.40-3.13)
Model III Reference 1.10 (0.69-0.74) 1.08 (0.67-1.72) 1.95 (1.27-3.00)
Model IV Reference 1.12 (0.69-1.83) 1.14 (0.70-1.85) 1.99 (1.26-3.13)
Model I: Aldosterone. Model II: Model I with adjustment for age and sex. Model III: Model II with additional adjustment for
systolic blood pressure, diabetes mellitus, history of myocardial infarction, body mass index, creatinine clearance, plasma
B-type natriuretic peptide levels and use of betablockers, diuretics, ACE-inhibition and angiotensin II-receptor blockers.
Model IV: Model III with additional adjustment for LDL-cholesterol, current smoking and plasma high-sensitivity C-
reactive protein levels.
Hazard ratios are reported with corresponding 95% conﬁdence intervals.
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increased across aldosterone quartiles. Compared with the lowest al-
dosterone quartile (b74 pg/mL), patients in the highest quartile
(≥137 pg/mL) had a 60% higher risk (HR 1.60 (1.16–2.21)) for the
combined vascular endpoint and a two times (HR 2.00 (1.30–3.07))
higher risk for vascular death, after adjustment for possible con-
founders (model III). For each quartile increment in plasma aldoste-
rone levels the risk of the combined vascular endpoint increased by
16% (HR 1.16 (1.05–1.29)) while the risk of vascular death increased
by 28% (HR 1.28 (1.11–1.47)) (model III) (Table 4). The associations
were only slightly altered after additional adjustment for other
established cardiovascular risk factors and hsCRP (model IV).
Cox proportional hazard analysis with aldosterone log-
transformed yielded comparable results. For presentation purposes,
results are displayed for quartile-based analyses.
Fig. 1 displays Cox proportional hazard survival curves according to
quartiles of aldosterone. The incidence of vascular events (Fig. 1A) and
vascular death (Fig. 1B) was highest in the upper aldosterone quartile,
as compared to the lowest. The associations between plasma aldoste-
rone levels and vascular events and between plasma aldosterone levelsTable 4
Hazard ratios for vascular death and the composite endpoint
increase in plasma aldosterone concentration.
MAJOR VASCULAR EVENT
HR 95% CI
Model I 1.20 1.09-1.
Model II 1.19 1.08-1.
Model III 1.15 1.04-1.
Model IV 1.14 1.02-1.
Model I: Aldosterone. Model II: Model I with adjustment for
systolic blood pressure, diabetes mellitus, history of myocar
B-type natriuretic peptide levels and use of betablockers, d
Model IV: Model III with additional adjustment for LDL‐c
reactive protein levels.
Hazard ratios are reported with corresponding 95% conﬁdeand vascular mortality were not modiﬁed by the duration of clinically
manifest CAD at baseline (p‐values for interaction 0.699 for vascular
events and 0.756 for vascular mortality) nor by presence of manifest
atherosclerotic disease at other locations (p=0.402 for vascular events
and p=0.427 for vascular mortality).3.4. Aldosterone levels and atherosclerotic burden
Univariable linear regression or logistic regression analysis, as ap-
propriate, showed baseline aldosterone (expressed in sex-pooled
quartiles) to be positively associated with both involvement of multi-
ple vascular territories and presence of carotid artery stenosis and
negatively associated with ankle‐brachial index (Table 5).
After correction for possible confounders (age, gender, systolic
blood pressure, diabetes mellitus, BMI, creatinine clearance, LDL-
cholesterol, hsCRP, current smoking) in multivariable regression anal-
ysis, the associations were attenuated. However, aldosterone was
still positively associated with involvement of multiple vascular
territories.of myocardial infarction, stroke or vascular death per quartile
S VASCULAR MORTALITY
HR 95% CI
32 1.32 1.16-1.50
31 1.29 1.13-1.47
28 1.26 1.10-1.45
26 1.27 1.10-1.47
age and sex. Model III: Model II with additional adjustment for
dial infarction, body mass index, creatinine clearance, plasma
iuretics, ACE-inhibition and angiotensin II-receptor blockers.
holesterol, current smoking and plasma high-sensitivity C-
nce intervals.
Follow up until occurrence of vascular event (years)
543210
Ev
en
t r
at
e
0,20
0,15
0,10
0,05
0,00
Aldosterone Quartile 4 (HR 1.72 [1.27-2.33], p-value 0.00) 
Aldosterone Quartile 3 (HR 1.14 [0.82-1.58], p-value 0.44)
Aldosterone Quartile 2 (HR 1.12 [0.81-1.56], p-value 0.50)
Aldosterone Quartile 1 (Reference)
Follow up until occurrence of vascular mortality (years)
543210
Ev
en
t r
at
e
0,12
0,10
0,08
0,06
0,04
0,02
0,00
Aldosterone Quartile 4 (HR 2.18 [1.45-3.26], p-value 0.00)
Aldosterone Quartile 3 (HR 1.12 [0.71-1.76], p-value 0.64)
Aldosterone Quartile 2 (HR 1.11 [0.70-1.75], p-value 0.65)
Aldosterone Quartile 1 (Reference)
A
B
Fig. 1. Cox proportional hazard (survival) curves according to quartiles of aldosterone.
Table 5
Aldosterone in relation to several indicators of atherosclerotic burden.
Model OR 95%CI p‐value
Multiple vascular territories affected
Model A 1.79 1.36 to 2.35 0.000
Model B 1.79 1.35 to 2.36 0.000
Model C 1.41 1.04 to 1.91 0.026
Carotid stenosis (>50%)
Model A 1.46 1.03 to 2.06 0.033
Model B 1.42 1.00 to 2.02 0.052
Model C 1.11 0.75 to 1.63 0.600
β 95%CI p‐value
ABI
Model A −0.040 −0.061 to –0.019 0.000
Model B −0.040 −0.060 to –0.019 0.000
Model C −0.013 −0.034 to +0.008 0.223
IMT (mm)
Model A 0.020 −0.010 to +0.050 0.196
Model B 0.018 −0.010 to +0.047 0.202
Model C 0.001 −0.029 to +0.030 0.960
Model A: Aldosterone. Model B: Model A with adjustment for age and sex. Model C:
Model B with additional adjustment for systolic blood pressure, diabetes mellitus,
body mass index, creatinine clearance, LDL, hsCRP and current smoking.
For logistic regression odd ratios (OR) are reported. For linear regression beta
regression coefﬁcients (β) are reported. Values for OR and β are reported for aldoste-
rone Quartile 4 vs. Quartile 1.
ABI: ankle-brachial index, IMT: carotid intima-media thickness.
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Aldosterone is known to be associated with mortality in high-risk
subgroups of patients with CAD. The present study is the ﬁrst to con-
ﬁrm this ﬁnding in a stable and low risk population of CAD patients
recruited in an outpatient clinic. In addition, this study further dem-
onstrates that aldosterone levels are associated with the risk of future
vascular events and with the degree of atherosclerotic burden. Ulti-
mately, these observations suggest a link between the aldosterone
pathway and the atherosclerotic process.
4.1. Aldosterone levels and vascular mortality in low risk and chronic
CAD patients
Although several previous studies have shown an association be-
tween aldosterone and vascular mortality in CAD patients [17–19],those studies were performed in ACS patients and no information
was reported about the effect of aldosterone levels on cardiovascular
risk in stable CAD patients. Recently, Tomaschitz et al. reported asso-
ciations of aldosterone with long-term mortality in 3153 patients
scheduled for coronary angiography; however, in that heterogeneous
population 23% did not have signiﬁcant CAD, while in the remaining
patients 40% presented with an ACS [20]. Similarly, the population
that we recently studied and where we found an association of aldo-
sterone levels with increased mortality risk, was a population of 807
patients undergoing an elective percutaneous coronary intervention,
of whom 26% had a very recent history of (2–7 days) of an ACS [21].
No separate analysis of patients with CAD but without ACS is current-
ly available. By contrast, our analyses presented herein uniquely fo-
cused on stable CAD patients recruited in an outpatient setting.
The low risk proﬁle of the present population, as compared to pa-
tients with an ACS, is reﬂected by the low level of CRP (2.0 mg/L) and
BNP (11 pmol/L) and by the low mortality rate: 23 per 1000 person
years. Thus, the present study conﬁrms that the previously
established increased vascular mortality risk associated with plasma
aldosterone levels is also present in a stable population of patients
with CAD.
While previous studies have demonstrated that an acute aldoste-
rone increase is associated with an increased (vascular) mortality
[13–19,23], the present study demonstrates that vascular mortality
is also related to aldosterone in the chronic phase.
Furthermore, the levels of aldosterone found in the present study
were within the normal range, as conﬁrmed by the same measure-
ments in healthy control subjects. This contrasts to the levels found
in heart failure patients, which are generally elevated as compared
to normal [14,15].
In conclusion, the link between aldosterone and vascular mortality
is time-independent of the ﬁrst clinical manifestation of CAD and is
associated with variations of aldosterone within the normal range.
This ﬁnding suggests that besides acute neuro-hormonal activation,
more subtle activation of the aldosterone pathway may be associated
with increased vascular mortality.
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Even though preclinical evidence has already linked aldosterone
to essential processes involved in atherosclerosis, such as vascular in-
ﬂammation, smooth muscle cell proliferation, endothelial dysfunc-
tion and intimal hyperplasia [8,24–28], clinical data conﬁrming
these ﬁndings have been lacking. In that regard, a particular strength
of the present study is that the association between aldosterone and
the risk for major vascular events, including MI and ischemic stroke,
was investigated. This relationship has never been established before.
In fact, to the best of our knowledge, this is the ﬁrst study to demon-
strate that plasma aldosterone levels are not only associated with an
increased risk of fatal vascular events but also with an increased risk
of major vascular events, including MI and ischemic stroke. The rela-
tionship between aldosterone levels and atherosclerotic burden
found in the present study supports this etiologic association. Taken
together, these results strongly suggest a relationship between the al-
dosterone pathway and the atherosclerotic process.
4.3. Limitations
We acknowledge some limitations of the study. First, due to the
observational, though prospective, character of the study, the associ-
ations found do not necessarily reﬂect causality. Although we
corrected for a substantial number of potential confounders, there
may be residual confounding factors not taken into account. Second,
results in this speciﬁc study population of stable CAD patients in an
outpatient clinic setting may not be completely generalizable to
other populations. Nevertheless, our results are in line with similar
ﬁndings in other cohorts, suggesting the associations identiﬁed are
not merely a coincidental ﬁnding speciﬁc to this one study popula-
tion. Third, it would have been interesting to study aldosterone levels
relative to renin levels. We would then have had an impression of the
level of relative RAAS activation. However, since renin levels were not
available, such analyses were not possible. Finally, although aldoste-
rone is known to be higher in patients with heart failure, left ventric-
ular ejection fraction and New York Heart Association functional class
were not recorded in our patients. However, BNP was measured and
BNP‐levels were within normal ranges and, thus, argue against sub-
stantial numbers of heart failure patients. Moreover, BNP was includ-
ed as a confounder in the multivariable models.
5. Conclusion
In conclusion, the present study is the ﬁrst to conﬁrm that the eti-
ologic relationship between plasma aldosterone levels and the risk of
major vascular events exists in a stable and low risk population of
CAD patients recruited in an outpatient clinic setting. This study fur-
ther demonstrates that aldosterone levels are associated with athero-
sclerotic burden, suggesting involvement of the aldosterone pathway
in the atherosclerotic process.
The ability to identify those patients at highest risk ofmajor vascular
events from among stable and chronic coronary patientswhootherwise
present at low risk will facilitate more effective monitoring and may
identify those patients who will most beneﬁt from more aggressive
treatment using existing therapeutic strategies. Hence, if future
research indicates clinical beneﬁt of aldosterone blockers in patients
with stable CAD, this therapy can be readily applied.
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